Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidyl-inositol 3-kinase (PI3K)–Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Signal
Main Authors: Tao, Jessica J., Castel, Pau, Radosevic-Robin, Nina, Elkabets, Moshe, Auricchio, Neil, Aceto, Nicola, Weitsman, Gregory, Barber, Paul, Vojnovic, Borivoj, Ellis, Haley, Morse, Natasha, Viola-Villegas, Nerissa Therese, Bosch, Ana, Juric, Dejan, Hazra, Saswati, Singh, Sharat, Kim, Phillip, Bergamaschi, Anna, Maheswaran, Shyamala, Ng, Tony, Penault-Llorca, Frédérique, Lewis, Jason S., Carey, Lisa A., Perou, Charles M., Baselga, José, Scaltriti, Maurizio
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4283215/
https://ncbi.nlm.nih.gov/pubmed/24667376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.2005125
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados